The global  FLT3 inhibitors market  is expected to reach $2,061.3 million in 2032 from $400.9 million in 2021 at a CAGR of 14.88% during the forecast period 2022-2032. The global FLT3 inhibitors market growth is expected to be driven by the introduction of novel products, the increasing incidence of acute myeloid leukemia, and the rising research and development investments, among others.

Recent Developments in the Global FLT3 Inhibitors Market

In March 2021, Astellas Pharma's Xospata (Gilteritinib) met the overall survival endpoint in the COMMODORE trial of subjects having FLT3 mutated relapsed or refractory acute myeloid leukemia.
In December 2021, Allarity Therapeutics submitted a New Drug Application (NDA) to the US FDA for Dovitinib as a third-line treatment for renal cell carcinoma (RCC).
In June 2021, Cullinan Oncology received Investigational New Drug (IND) Clearance from the FDA for CLN-049 to treat relapsed/refractory AML.
In June 2019, Daiichi Sankyo Company, Limited received a Complete Response Letter (CRL) from the US FDA for the New Drug Application (NDA) of Vanflyta (Quizartinib) to treat adult patients with relapsed/ refractory FLT3-ITD acute myeloid leukemia.

Demand Drivers and Limitations

Following are the demand drivers for the global FLT3 inhibitors market:

Introduction of Novel Products
Increasing Incidence of Acute Myeloid Leukemia
Rising Research and Development Investments

The market is expected to face some limitations too due to the following challenges:

High Treatment Cost Impacting the Adoption Rate
Disease Relapse in FLT3 Mutated AML

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

Cullinan Oncology, LLC
Astellas Pharma Inc.
Allarity Therapeutics, Inc.
AROG Pharmaceuticals, Inc.
Aptose Biosciences Inc.
Novartis International AG
Daiichi Sankyo Company, Limited
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
FUJIFILM Pharmaceuticals USA, Inc.
Jiangsu Heng Rui Medicine Co., Ltd.

BIS Related Studies

Hematological Malignancies Emerging Therapeutics Market - A Global and Regional Analysis